IP Library Granted Patent US 7,169,899
Granted Patent B1
US 7,169,899 · App. 09/679,331 · Granted Jan 30, 2007

Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,169,899
App. No.
09/679,331
Granted
Jan 30, 2007
Kind
B1
Abstract

A library of macrocyclic compounds of the formula (I) where part (A) is a bivalent radical, a —(CH 2 ) y — bivalent radical or a covalent bond; where part (B) is a bivalent radical, a —(CH 2 ) z — bivalent radical, or a covalent bond; where part (C) is a bivalent radical, a —(CH 2 ) t — bivalent radical, or a covalent bond; and where part (T) is a —Y—L—Z— radical wherein number Y is CH 2 or CO, Z is NH or O and L is a bivalent radical. These compounds are useful for carrying out screening assay or as intermediates for the synthesis of other compound of pharmaceutical interest. A process for their preparation of these compounds in a combinatorial manner, is also disclosed.

Claims (21)

1. A macrocyclic compound of the formula (1):

and its pharmaceutically acceptable salts,

wherein

A 1 is:

wherein

X 1 is —CH—, and

R 1 is

A 2 is:

wherein

X 2 is —CH—, and

R 2 is H;

A 3 is:

wherein

X 3 is —CH—, and

R 3 is

W 1 , W 2 , W 3 , and W 5 are each selected from the group consisting of hydrogen and protecting groups used for orthogonal protection in peptide synthesis;

wherein the carbonyl carbon of A 1 is covalently bonded to the nitrogen atom of A 2 , and the carbonyl carbon of A 2 is covalently bonded to the nitrogen atom of A 3 ;

T is a radical selected from the group consisting of:

wherein (N) is the nitrogen atom of A 1 of formula (1) and (C) is the carbonyl carbon of A 3 of formula (1).

2. A macrocyclic compound of the formula (1) as defined in claim 1 , wherein W 1 , W 2 , W 3 , and W 5 are each selected from the group consisting of hydrogen and a compatible protecting group chosen from:

3. A macrocyclic compound of the formula (1) as defined in claim 1 , wherein W 1 , W 2 , W 3 , and W 5 each represents hydrogen.

Assignments (2)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 044949, FRAME 0634 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0460 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Dec 22, 2017
From: OCERA THERAPEUTICS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 044949/0634 →